Natalizumab in the pediatric MS population: Results of the Italian registry

BMC Neurology

Volumn 15, Issue 1, 2015, Pages

  Ghezzi, Angelo ^a   Moiola, Lucia ^b   Pozzilli, Carlo ^c   Brescia Morra, Vincenzo ^d   Gallo, Paolo ^e   Grimaldi, Luigi Maria Edoardo ^f   Filippi, Massimo ^g   G , Giancarlo Comi ^b  

^a Hospital of Gallarate   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Fondazione Istituto San Raffaele G Giglio   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NATALIZUMAB;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE CYST; BRAIN DAMAGE; CHILD; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION; ITALY; JC VIRUS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; PROTEINURIA; PRURITUS; RECURRENCE RISK; RELAPSE; RESPIRATORY TRACT DISEASE; RESTLESSNESS; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VERTIGO; WEIGHT REDUCTION; RECURRENT DISEASE; REGISTER;

ADOLESCENT; CHILD; FEMALE; GLATIRAMER ACETATE; HUMANS; INTERFERON-BETA; ITALY; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; NATALIZUMAB; RECURRENCE; REGISTRIES;

EID: 84942155555     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-015-0433-y     Document Type: Article

References (17)

1. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014;13:936-48.
2. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, et al. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013;80:1161-8.
3. Ghezzi A, Banwell B, Boyko A, Amato MP, Anlar B, Blinkenberg M, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010;16:1258-67.
4. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Arch Neurol. 2011;68:437-44.
5. Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75:912-7.
6. Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19:1106-12.
7. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65:1655-8.
8. Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010;3:293-9.
9. Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70:469-75.
10. Arnal-Garcia C, García-Montero MR, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramió-Torrentà L, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. 2013;17:50-4.
11. Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190-7.
12. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10:745-58.
13. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295-303.
14. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802-12.
15. Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18:116-27.
16. Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18:143-52.
17. Moiola L, Sangalli F, Martinelli V. Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiple sclerosis patients from Italy. Neurology Suppl. 2011;S30(007):A375.